Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an update.
Australian Clinical Labs has cancelled 539,443 ordinary fully paid shares as part of an on-market share buy-back, with the cessation of these securities effective 10 April 2026. The reduction in issued capital may marginally enhance earnings per share and signals ongoing capital management, with implications for shareholder value and the company’s balance sheet structure.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian-listed healthcare company operating in the medical diagnostics and pathology testing industry. It provides laboratory testing services to healthcare providers and patients, with its ordinary fully paid shares trading on the ASX under the ticker ACL.
Average Trading Volume: 813,579
Technical Sentiment Signal: Sell
Current Market Cap: A$390.6M
See more data about ACL stock on TipRanks’ Stock Analysis page.